These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27449495)

  • 1. Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.
    Slim M; Medina-Caliz I; Gonzalez-Jimenez A; Cabello MR; Mayoral-Cleries F; Lucena MI; Andrade RJ
    Drug Saf; 2016 Oct; 39(10):925-43. PubMed ID: 27449495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review.
    Xu H; Zhuang X
    Neuropsychiatr Dis Treat; 2019; 15():2087-2099. PubMed ID: 31413575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and tolerability of atypical antipsychotics in bipolar disorder.
    Seemüller F; Forsthoff A; Dittmann S; Born C; Bernhard B; Severus WE; Grunze H
    Expert Opin Drug Saf; 2005 Sep; 4(5):849-68. PubMed ID: 16111448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotic tolerability and switching strategies in bipolar disorder.
    Liauw SS; McIntyre RS
    Expert Opin Pharmacother; 2010 Dec; 11(17):2827-37. PubMed ID: 20726821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging treatments for bipolar disorder: safety and adverse effect profiles.
    Marken PA; Pies RW
    Ann Pharmacother; 2006 Feb; 40(2):276-85. PubMed ID: 16403851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives.
    Singh R; Bansal Y; Medhi B; Kuhad A
    Eur J Pharmacol; 2019 Feb; 844():231-240. PubMed ID: 30529195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic effects of atypical antipsychotics: Molecular targets.
    Fonseca M; Carmo F; Martel F
    J Neuroendocrinol; 2023 Dec; 35(12):e13347. PubMed ID: 37866818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-emergent adverse events associated with atypical antipsychotics.
    Cha DS; McIntyre RS
    Expert Opin Pharmacother; 2012 Aug; 13(11):1587-98. PubMed ID: 22304541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder.
    McIntyre RS; Konarski JZ
    J Clin Psychiatry; 2005; 66 Suppl 3():28-36. PubMed ID: 15762832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.
    Jafari S; Fernandez-Enright F; Huang XF
    J Neurochem; 2012 Feb; 120(3):371-84. PubMed ID: 22103329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.
    Yan H; Chen JD; Zheng XY
    Psychopharmacology (Berl); 2013 Sep; 229(1):1-7. PubMed ID: 23832387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
    Perlis RH
    Am J Manag Care; 2007 Nov; 13(7 Suppl):S178-88. PubMed ID: 18041879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of bipolar mania with atypical antipsychotics.
    Chengappa KN; Suppes T; Berk M
    Expert Rev Neurother; 2004 Nov; 4(6 Suppl 2):S17-25. PubMed ID: 16279862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.